The standard first-line treatment approach for PC is androgen deprivation therapy (ADT), as it is primarily a hormone-driven disease overexpressing both prostate-specific antigen (PSA) and androgen receptor (AR) proteins [3]. The gene discussed is AR; the disease is pachyonychia congenita.